Respiratory syncytial virus infectious disease

This study tests an RSV vaccine in pregnant women living with HIV. The goal is to see if the vaccine is safe and helps mothers pass protective antibodies to their babies, potentially preventing severe RSV lung infections in infants. The trial involves about 681 pregnant participa…

This phase 3 study tested a single dose of an investigational RSV vaccine in 751 adults aged 60 and older, and those 50-59 at increased risk for severe RSV. The goal was to see how well the vaccine boosts the immune system and whether it is safe. Participants received either the …

This study tested an mRNA vaccine (mRNA-1345) against respiratory syncytial virus (RSV) in 360 pregnant women. The goal was to see if the vaccine is safe for mothers and their babies, and whether it triggers an immune response that could protect infants after birth. Participants …

This study tested an experimental RSV vaccine in adults who had a lung or kidney transplant, as well as in healthy adults over 50. The goal was to see if the vaccine could safely boost their immune response against RSV, a common and potentially serious respiratory virus. Research…

This study tested an experimental RSV vaccine in adults aged 60 and older in China. The goal was to see if the vaccine produces a strong immune response similar to that seen in older adults from other countries, where the vaccine already proved effective. About 2,620 participants…

This study tested a new nasal spray vaccine for respiratory syncytial virus (RSV), a common cause of serious breathing problems in babies and young children. The vaccine was given as nose drops to 88 healthy children aged 4 months to 5 years, including those who had and had not b…

This early-stage study tested six different mRNA vaccine formulations against respiratory syncytial virus (RSV) in 240 healthy adults aged 18 to 49. The goal was to check safety and how well the vaccines trigger an immune response. Each participant received a single shot and was …

This Phase 1 study tests a new vaccine that aims to protect against three respiratory viruses at once: RSV, hMPV, and PIV3. The trial involves 390 adults aged 60 and older and will check if the vaccine is safe and helps the body produce antibodies. Different combinations and dose…

This completed study in Japan checked the safety of the RSV vaccine Abrysvo in 497 pregnant women and their infants. Researchers tracked side effects in mothers for 28 days after vaccination and in babies from birth to 28 days old. The goal was to confirm the vaccine's safety in …

This study tested a new vaccine designed to protect against two respiratory viruses: RSV and hMPV. It involved 646 healthy adults aged 60 and older who received either the vaccine or a placebo. The goal was to see if the vaccine is safe and triggers a strong immune response, with…

This study tested the safety and immune response of several Moderna mRNA vaccines for COVID-19, seasonal flu, RSV, and CMV in 308 healthy adults aged 18 to 75. Researchers monitored side effects and measured antibody levels after vaccination. The goal was to ensure the vaccines a…

This study tested an experimental RSV vaccine in about 4500 adults aged 60 and older. Half received the vaccine and half received a placebo shot. The goal was to see if the vaccine could prevent lower respiratory tract disease caused by RSV, a common virus that can be serious in …

This early-stage study tested two experimental RSV vaccines given as nose drops in 60 children. Some children already had RSV antibodies (ages 1-5) and some did not (ages 6 months-2 years). The main goals were to check safety and whether the vaccines triggered an immune response.

This study tested an RSV vaccine in 378 older adults (60+) in Korea to see if it is safe and helps the body fight the virus. Participants received either the vaccine or a placebo and were monitored for side effects and immune response. The results showed the vaccine was well tole…

This study tested a live, weakened RSV vaccine given as a nasal spray to infants and toddlers aged 6 to 24 months in Puerto Rico. The main goal was to see if the vaccine virus spreads from vaccinated children to others in the same household or daycare, and to check how long the v…

This early-stage study tested the safety and immune response of new vaccines that combine protection against flu, RSV, hMPV, and PIV3 in healthy adults aged 18 to 49. Participants received a single shot of one of several vaccine formulas. The goal was to see if these combination …

This phase 3 study tested an mRNA vaccine called mRNA-1345 to protect against respiratory syncytial virus (RSV) in adults aged 50 and older. Over 3,300 participants received the vaccine alone, with a flu shot, or with a COVID-19 booster. The trial also looked at a booster dose on…

This completed phase 3 trial tested whether giving an RSV vaccine and a COVID-19 mRNA vaccine at the same time is as safe and effective as giving them separately. About 841 adults aged 50 and older took part. Researchers measured immune responses and side effects one month after …

This study tested a new vaccine called IVX-A12 that targets two respiratory viruses: RSV and hMPV. It involved 264 healthy adults aged 60 to 85. The goal was to see if the vaccine is safe and boosts the immune system to fight these viruses.

This early-stage trial tested a new vaccine designed to protect against both RSV and hMPV, two common respiratory viruses. 385 healthy adults aged 60 to 75 received a single injection of different doses. The main goals were to check safety and measure the immune response. Results…

This large phase 3 study tested an experimental RSV vaccine in over 25,000 adults aged 60 and older. The goal was to see if a single shot could prevent lower respiratory tract disease caused by RSV, a common virus that can be dangerous for seniors. Participants received either th…

This study tested whether giving the RSV vaccine (Abrysvo) and the shingles vaccine (Shingrix) at the same doctor's visit is safe and works as well as giving them separately. About 526 adults aged 50 and older took part. Researchers measured immune responses and tracked side effe…

This completed study looked at how well licensed RSV vaccines (Pfizer's Abrysvo or GSK's Arexvy) trigger an immune response in adults over 60 living in long-term care facilities compared to those living independently in the community. Researchers measured antibody levels before a…

This study tested an RSV vaccine in 453 healthy women aged 18-49. It compared a multidose vial with a preservative to a single-dose vial without one. The goal was to see if both versions are safe and produce a similar immune response. Participants received one shot and were follo…

This study tested an experimental RSV vaccine in about 1,500 adults. It compared the immune response and safety in younger adults (18-49 years) who are at increased risk for RSV disease to older adults (60 years and older). The goal was to see if the vaccine works as well in the …

This early-stage trial tested an experimental mRNA vaccine designed to protect against two respiratory viruses: RSV and hMPV. Healthy adults aged 18 to 49 and 60 years and older received a single injection of the vaccine at different doses. The main goals were to check safety and…

This study tested a live-attenuated RSV vaccine given as a nasal spray in 259 infants and toddlers aged 6 to 18 months. The main goals were to check safety and measure the immune response. Researchers also looked at how much vaccine virus was shed and how well the vaccine worked …

This study tested a new mRNA booster shot (mRNA-1345) in 507 adults aged 60 and older who had already received a licensed RSV vaccine at least a year earlier. The goal was to see if the booster is safe and boosts the immune system's ability to fight RSV. Researchers measured side…

This study looked at the safety and how the body processes two doses of nirsevimab, a medicine to prevent RSV, given 5 to 6 months apart. It included 33 Japanese infants up to 12 months old with heart or lung disease, weak immune systems, Down syndrome, or who were born early. Re…

This study tested whether the antiviral drug Amizon (enisamium iodide) can help adults with colds or flu feel better faster. One hundred adults aged 18 to 60 took either Amizon or a placebo pill for 7 days, starting within a day of their first symptoms. Researchers tracked sympto…

This study looked at whether giving hospital-level care to acutely ill adults in their own homes in rural areas works well. 160 people with various conditions like infections, heart failure, or COPD took part. The goal was to see if this approach could lower costs and help patien…

This study tested an experimental oral drug called EDP-323 in 142 healthy adults who were deliberately infected with RSV. The goal was to see if the drug is safe and can reduce the amount of virus in the nose compared to a placebo. Results will help determine if EDP-323 could be …

This study tested two new rapid tests that use a single nose swab to detect COVID-19, influenza A/B, and RSV. Researchers checked how accurate the tests are compared to standard lab methods and whether healthcare workers find them easy to use. The study involved 589 people with s…

This study collected nasal swabs, throat swabs, and saliva samples from 79 people with symptoms of flu, RSV, or COVID-19. The samples were used to help evaluate a point-of-care device called LumiraDx, which aims to quickly and accurately detect these viruses. The study focused on…

This study looked at how well a new, quick finger-prick test (LumiraDx CRP) measures CRP levels compared to a standard lab test. CRP is a marker of infection, inflammation, or tissue injury. 79 adults with symptoms of these conditions took part. The goal was to see if the new tes…

This study tested a new rapid test (LumiraDx Influenza A/B + RSV Test) that uses a nasal swab to quickly detect flu A, flu B, and RSV. Over 500 people with cold or flu-like symptoms took part. The test was performed by healthcare workers at point-of-care sites and compared to sta…

This study tested whether giving general practitioners a rapid C-reactive protein (CRP) test helps them decide when antibiotics are truly needed for patients with respiratory infections. 140 patients with symptoms like cough, fever, or sore throat took part. Doctors in the test g…

This study checked how well a new test called VitaSIRO solo™ detects COVID-19, flu, and RSV in people with respiratory symptoms. Over 1,200 participants provided nose and throat swabs. The test's accuracy was compared to standard lab methods.

This study tested a new rapid test that checks for flu A, flu B, COVID-19, and RSV using one nasal swab. Over 1,100 people with respiratory symptoms took part. The goal was to see how well the test works compared to standard lab tests.

This early study tested whether a special PET scan using a radioactive form of vitamin B9 (11C-PABA) can help doctors see infections deep inside the body. Researchers scanned 13 healthy people and patients with known or suspected infections. The goal was to see if this method can…

This study looked at whether FebriDx, a rapid fingerstick test, can accurately tell bacterial from non-bacterial acute respiratory infections when used by people without lab training. Researchers compared results from untrained operators to trained ones in 800 patients with fever…

This study looked at two new ways to prevent RSV, a serious lung infection in babies: a vaccine given to pregnant women and an antibody shot given to infants. Researchers wanted to see how well each method works alone or together. 181 mother-infant pairs took part, and the study …

This study tested a new medicine called clesrovimab in over 1,000 infants and children at high risk for severe RSV disease. The goal was to see if it is safe and works as well as or better than the current standard treatment, palivizumab. Participants received either clesrovimab …

This study tested a single dose of nirsevimab, a lab-made antibody, in 800 healthy preterm and term infants in China to see if it could prevent serious lung infections caused by RSV. The goal was to reduce doctor visits and hospital stays during the RSV season. Results showed the…

This study tested an injection called TNM001 in over 2,200 babies under 1 year old to see if it could prevent serious lung infections caused by RSV. The goal was to reduce the number of babies who get sick enough to need medical care. The study compared the shot to a placebo to c…

This study tested a new medicine called TNM001 to prevent severe RSV lung infections in high-risk infants under 1 year old. About 201 babies received either the antibody or a placebo, and were monitored for 270 days. The goal was to see if the antibody could safely reduce serious…

This large study tested a new medicine called clesrovimab to prevent RSV, a serious lung infection, in healthy babies born early or full-term. Over 3,600 infants received either the medicine or a placebo. The goal was to see if the medicine could reduce the number of babies who g…

This study looked at whether a single shot of nirsevimab (Beyfortus) can prevent RSV and other respiratory infections in infants under 1 year old. Researchers reviewed medical records from 816 babies at seven hospitals in China, comparing those who got the shot to those who did n…

This study tested whether the dietary supplement MitoQ could prevent severe viral infections, like COVID-19, in adults who had close contact with a sick person. Eighty asymptomatic adults were given MitoQ or no treatment and monitored for illness. The goal was to see if the suppl…

This study tested different strategies to increase RSV vaccination among 50 pregnant people. The goal was to find the best way to encourage vaccination at the right time during pregnancy to protect newborns from severe RSV. The study compared early and late vaccination timing alo…

This study looked at how well a single dose of BEYFORTUS (nirsevimab) protects infants from serious RSV infections that require a doctor visit or hospital stay. Researchers followed nearly 50,000 babies during their first RSV season. The goal was to see if the shot reduces cases …

This study tested a single injection of nirsevimab in over 8,000 healthy infants under 1 year old to see if it could prevent hospitalizations from RSV, a common respiratory virus. Babies received either the shot or no intervention and were followed for up to 6 months. The goal wa…

This study looked at whether giving a low dose of a muscle relaxant (rocuronium) during bronchoscopy—a procedure where a tube is inserted into the lungs—could reduce complications like throat spasms and coughing. 153 adults having elective bronchoscopy were split into two groups:…

This study tracks how many infants in Germany receive nirsevimab, a long-acting antibody that helps protect against severe RSV disease. Researchers will survey parents of babies born during three RSV seasons (2024–2027) to measure immunization rates. The goal is to see how well t…

This study looked at 537 patients with respiratory infection symptoms to see how the types of viruses and bacteria changed from the COVID-19 pandemic period to after it. Researchers used a special PCR test to detect multiple germs at once. The goal was to understand how pandemic …

This study looked at how the immune system of healthy adults aged 65-75 responds to RSV, a common cause of chest infections. Researchers gave volunteers a mild RSV infection and took blood and nose samples to find immune markers linked to protection. The goal is to use these find…

This study checked how accurate a new test (Xpert Expanded Respiratory Panel) is at finding respiratory infections. Researchers tested nose swabs from 3,200 people with symptoms and compared results to other tests. The goal was to see if the new test works well enough for routine…

This study tested whether adding infectious disease experts to primary care teams helps reduce unnecessary antibiotic use. Over 1,300 patients from six clinics in Spain took part. Doctors in the expert-advised group could call or meet with specialists to discuss tricky cases. The…

This study followed over 3,800 women who had received an RSV vaccine or a placebo in a previous pregnancy to see if it was safe in later pregnancies. No new vaccine was given—researchers just tracked pregnancy outcomes and baby health up to 42 days after birth. The goal was to de…

This study looked at whether new RSV prevention medicines given to infants or pregnant women reduced hospitalizations for RSV in children under 2. Researchers analyzed health records from over 2,700 children in the Australian Capital Territory. The goal was to see if the 2025 pre…

This study tested a program to help doctors prescribe antibiotics more appropriately for common childhood infections like earaches, sore throats, and sinusitis. Over 1,000 doctors took part, receiving online training, personalized feedback on their prescribing habits, and support…

This study looked at how the immune system of older adults (ages 60-75) responds to a controlled infection with respiratory syncytial virus (RSV). Researchers gave 28 healthy volunteers a weakened form of the virus via nasal drops and monitored their symptoms and immune reactions…

This study tested a computer tool that helps nurses decide when antibiotics are needed for common respiratory infections like colds and sore throats. The tool, built into the electronic health record, calculates a patient's risk and suggests appropriate care. Researchers measured…

This study looked at 156 critically ill patients to find out what factors help achieve the right levels of beta-lactam antibiotics in the blood. Researchers collected clinical data and used therapeutic drug monitoring to see which patients reached target concentrations. The goal …

This study looked at how a new medicine called nirsevimab affected RSV infections and hospital stays in children under 2 years old in the Australian Capital Territory. Researchers used routine health data from over 2,300 kids to compare RSV cases and emergency visits before and a…

This completed study looked at how a special form of vitamin B3 (nicotinamide) is processed in 28 patients with low tryptophan levels due to respiratory infections or inflammatory bowel disease. Participants took either 500 mg or 1000 mg of the supplement daily for four weeks. Th…